Tag: book

PALM BEACH, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- New America Acquisition I Corp. ("NAA" or the "SPAC"), a blank check company targeting businesses with a focus on American values and priorities, announced today that it has filed a registration statement on Form S-1 (the "Registration Statement") with the Securities and Exchange Commission (the "SEC") in connection with a proposed initial public offering of its units. The Florida-based company plans to raise $300 million by offering 30 million units at $10 per unit. Each unit consists of one share of Class A common stock and one-half of a warrant, with each whole warrant exercisable for one share of Class A common stock at $11.50 per share.

CHICAGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Vivid Seats Inc. (NASDAQ: SEAT) (“Vivid Seats”), a leading marketplace that utilizes its technology platform to connect millions of buyers with thousands of ticket sellers across hundreds of thousands of events each year, today announced a 1-for-20 reverse stock split of its Class A and Class B common stock (the “Reverse Stock Split”), effective at 5:00 p.m. Eastern Time on August 5, 2025. The Class A common stock will begin trading on the Nasdaq Global Select Market on a split-adjusted basis under the existing ticker symbol “SEAT” when the market opens on August 6, 2025. The new CUSIP number for the Class A common stock following the Reverse Stock Split is 92854T209.

SINGAPORE, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Ostium, a decentralized trading platform, has announced the launch of a new leveraged trading instrument: 0DTE perpetuals for equities. The instrument combines intraday expiry with perpetual structure, offering day traders up to 100x leverage on individual stocks during market hours — a structural innovation aimed at addressing the limitations of traditional options and CFDs.

CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of 43,700,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 5,700,000 additional shares of its common stock, at a public offering price of $3.30 per share. The underwriters did not receive any discounts or commissions with respect to an aggregate of 1,818,181 shares of common stock sold to the Cystic Fibrosis Foundation. All of the shares of common stock in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $144.2 million.

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES